WINREVAIR Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
FDA Approves Merck's KEYTRUDA QLEX Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA®
Merck Receives Positive EU CHMP Opinion for ENFLONSIA for the Prevention of Respiratory Syncytial Virus in Infants During Their First RSV Season
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® , for Subcutaneous Administration and for New Indication for Earlier-Stage Head and Neck Cancer
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
CAPVAXIVE® Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering
